Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells

Penn Muluhngwi, Abirami Krishna, Stephany L. Vittitow, Joshua T. Napier, Kirsten M. Richardson, Mackenzie Ellis, Justin L Mott, Carolyn M. Klinge

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Endocrine-resistance develops in ∼40% of breast cancer patients after tamoxifen (TAM) therapy. Although microRNAs are dysregulated in breast cancer, their contribution to endocrine-resistance is not yet understood. Previous microarray analysis identified miR-29a and miR-29b-1 as repressed by TAM in MCF-7 endocrine-sensitive breast cancer cells but stimulated by TAM in LY2 endocrine-resistant breast cancer cells. Here we examined the mechanism for the differential regulation of these miRs by TAM in MCF-7 versus TAM-resistant LY2 and LCC9 breast cancer cells and the functional role of these microRNAs in these cells. Knockdown studies revealed that ERα is responsible for TAM regulation of miR-29b-1/a transcription. We also demonstrated that transient overexpression of miR-29b-1/a decreased MCF-7, LCC9, and LY2 proliferation and inhibited LY2 cell migration and colony formation but did not sensitize LCC9 or LY2 cells to TAM. Furthermore, TAM reduced DICER1 mRNA and protein in LY2 cells, a known target of miR-29. Supporting this observation, anti-miR-29b-1 or anti-miR-29a inhibited the suppression of DICER by 4-OHT. These results suggest miR-29b-1/a has tumor suppressor activity in TAM-resistant cells and does not appear to play a role in mediating TAM resistance.

Original languageEnglish (US)
Pages (from-to)230-238
Number of pages9
JournalCancer Letters
Volume388
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Tamoxifen
Breast Neoplasms
MicroRNAs
Microarray Analysis
Cell Movement
Messenger RNA

Keywords

  • Breast cancer
  • Endocrine-resistance
  • Estrogen receptor
  • miRNA-29a
  • miRNA-29b-1
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Muluhngwi, P., Krishna, A., Vittitow, S. L., Napier, J. T., Richardson, K. M., Ellis, M., ... Klinge, C. M. (2017). Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Cancer Letters, 388, 230-238. https://doi.org/10.1016/j.canlet.2016.12.007

Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. / Muluhngwi, Penn; Krishna, Abirami; Vittitow, Stephany L.; Napier, Joshua T.; Richardson, Kirsten M.; Ellis, Mackenzie; Mott, Justin L; Klinge, Carolyn M.

In: Cancer Letters, Vol. 388, 01.03.2017, p. 230-238.

Research output: Contribution to journalArticle

Muluhngwi, Penn ; Krishna, Abirami ; Vittitow, Stephany L. ; Napier, Joshua T. ; Richardson, Kirsten M. ; Ellis, Mackenzie ; Mott, Justin L ; Klinge, Carolyn M. / Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. In: Cancer Letters. 2017 ; Vol. 388. pp. 230-238.
@article{e8513446e0184c94a2ff322c100b8995,
title = "Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells",
abstract = "Endocrine-resistance develops in ∼40{\%} of breast cancer patients after tamoxifen (TAM) therapy. Although microRNAs are dysregulated in breast cancer, their contribution to endocrine-resistance is not yet understood. Previous microarray analysis identified miR-29a and miR-29b-1 as repressed by TAM in MCF-7 endocrine-sensitive breast cancer cells but stimulated by TAM in LY2 endocrine-resistant breast cancer cells. Here we examined the mechanism for the differential regulation of these miRs by TAM in MCF-7 versus TAM-resistant LY2 and LCC9 breast cancer cells and the functional role of these microRNAs in these cells. Knockdown studies revealed that ERα is responsible for TAM regulation of miR-29b-1/a transcription. We also demonstrated that transient overexpression of miR-29b-1/a decreased MCF-7, LCC9, and LY2 proliferation and inhibited LY2 cell migration and colony formation but did not sensitize LCC9 or LY2 cells to TAM. Furthermore, TAM reduced DICER1 mRNA and protein in LY2 cells, a known target of miR-29. Supporting this observation, anti-miR-29b-1 or anti-miR-29a inhibited the suppression of DICER by 4-OHT. These results suggest miR-29b-1/a has tumor suppressor activity in TAM-resistant cells and does not appear to play a role in mediating TAM resistance.",
keywords = "Breast cancer, Endocrine-resistance, Estrogen receptor, miRNA-29a, miRNA-29b-1, Tamoxifen",
author = "Penn Muluhngwi and Abirami Krishna and Vittitow, {Stephany L.} and Napier, {Joshua T.} and Richardson, {Kirsten M.} and Mackenzie Ellis and Mott, {Justin L} and Klinge, {Carolyn M.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.canlet.2016.12.007",
language = "English (US)",
volume = "388",
pages = "230--238",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells

AU - Muluhngwi, Penn

AU - Krishna, Abirami

AU - Vittitow, Stephany L.

AU - Napier, Joshua T.

AU - Richardson, Kirsten M.

AU - Ellis, Mackenzie

AU - Mott, Justin L

AU - Klinge, Carolyn M.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Endocrine-resistance develops in ∼40% of breast cancer patients after tamoxifen (TAM) therapy. Although microRNAs are dysregulated in breast cancer, their contribution to endocrine-resistance is not yet understood. Previous microarray analysis identified miR-29a and miR-29b-1 as repressed by TAM in MCF-7 endocrine-sensitive breast cancer cells but stimulated by TAM in LY2 endocrine-resistant breast cancer cells. Here we examined the mechanism for the differential regulation of these miRs by TAM in MCF-7 versus TAM-resistant LY2 and LCC9 breast cancer cells and the functional role of these microRNAs in these cells. Knockdown studies revealed that ERα is responsible for TAM regulation of miR-29b-1/a transcription. We also demonstrated that transient overexpression of miR-29b-1/a decreased MCF-7, LCC9, and LY2 proliferation and inhibited LY2 cell migration and colony formation but did not sensitize LCC9 or LY2 cells to TAM. Furthermore, TAM reduced DICER1 mRNA and protein in LY2 cells, a known target of miR-29. Supporting this observation, anti-miR-29b-1 or anti-miR-29a inhibited the suppression of DICER by 4-OHT. These results suggest miR-29b-1/a has tumor suppressor activity in TAM-resistant cells and does not appear to play a role in mediating TAM resistance.

AB - Endocrine-resistance develops in ∼40% of breast cancer patients after tamoxifen (TAM) therapy. Although microRNAs are dysregulated in breast cancer, their contribution to endocrine-resistance is not yet understood. Previous microarray analysis identified miR-29a and miR-29b-1 as repressed by TAM in MCF-7 endocrine-sensitive breast cancer cells but stimulated by TAM in LY2 endocrine-resistant breast cancer cells. Here we examined the mechanism for the differential regulation of these miRs by TAM in MCF-7 versus TAM-resistant LY2 and LCC9 breast cancer cells and the functional role of these microRNAs in these cells. Knockdown studies revealed that ERα is responsible for TAM regulation of miR-29b-1/a transcription. We also demonstrated that transient overexpression of miR-29b-1/a decreased MCF-7, LCC9, and LY2 proliferation and inhibited LY2 cell migration and colony formation but did not sensitize LCC9 or LY2 cells to TAM. Furthermore, TAM reduced DICER1 mRNA and protein in LY2 cells, a known target of miR-29. Supporting this observation, anti-miR-29b-1 or anti-miR-29a inhibited the suppression of DICER by 4-OHT. These results suggest miR-29b-1/a has tumor suppressor activity in TAM-resistant cells and does not appear to play a role in mediating TAM resistance.

KW - Breast cancer

KW - Endocrine-resistance

KW - Estrogen receptor

KW - miRNA-29a

KW - miRNA-29b-1

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85007155243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007155243&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.12.007

DO - 10.1016/j.canlet.2016.12.007

M3 - Article

VL - 388

SP - 230

EP - 238

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -